XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $112.72 million. The enterprise value is -$62.60 million.
Important Dates
The next estimated earnings date is Friday, March 14, 2025, after market close.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.48 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 30.48M |
| Shares Outstanding | 30.48M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 34.89% |
| Owned by Institutions (%) | 16.19% |
| Float | 19.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.57, with a Debt / Equity ratio of 0.05.
| Current Ratio | 11.57 |
| Quick Ratio | 11.51 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.17 |
Financial Efficiency
Return on equity (ROE) is -15.75% and return on invested capital (ROIC) is -12.45%.
| Return on Equity (ROE) | -15.75% |
| Return on Assets (ROA) | -12.03% |
| Return on Capital (ROIC) | -12.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$398,268 |
| Employee Count | 82 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -90,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.43% in the last 52 weeks. The beta is 1.44, so XBiotech's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -19.43% |
| 50-Day Moving Average | 5.70 |
| 200-Day Moving Average | 6.78 |
| Relative Strength Index (RSI) | 29.89 |
| Average Volume (20 Days) | 84,725 |
Short Selling Information
The latest short interest is 770,655, so 2.53% of the outstanding shares have been sold short.
| Short Interest | 770,655 |
| Short Previous Month | 775,226 |
| Short % of Shares Out | 2.53% |
| Short % of Float | 3.88% |
| Short Ratio (days to cover) | 7.63 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.31M |
| Pretax Income | -30.44M |
| Net Income | -32.66M |
| EBITDA | -40.57M |
| EBIT | -42.31M |
| Earnings Per Share (EPS) | -$1.08 |
Full Income StatementBalance Sheet
The company has $183.12 million in cash and $10.00 million in debt, giving a net cash position of $173.12 million or $5.68 per share.
| Cash & Cash Equivalents | 183.12M |
| Total Debt | 10.00M |
| Net Cash | 173.12M |
| Net Cash Per Share | $5.68 |
| Equity (Book Value) | 192.12M |
| Book Value Per Share | 6.30 |
| Working Capital | 169.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.86 million and capital expenditures -$1.34 million, giving a free cash flow of -$29.19 million.
| Operating Cash Flow | -27.86M |
| Capital Expenditures | -1.34M |
| Free Cash Flow | -29.19M |
| FCF Per Share | -$0.96 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |